<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569828</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2205</org_study_id>
    <secondary_id>2007-005482-36</secondary_id>
    <nct_id>NCT01569828</nct_id>
  </id_info>
  <brief_title>Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function</brief_title>
  <official_title>An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      An open label, parallel-group study to determine multiple dose pharmacokinetics of LCZ696 and
      its metabolites in subjects with severe renal impairment compared to matched healthy subjects
      with normal renal function
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>1 and 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Cmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>1 and 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-24h After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</measure>
    <time_frame>1 and 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 After Multiple Dose Administration (Day 5)</measure>
    <time_frame>5 days</time_frame>
    <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F After Multiple Dose Administration (Day 5)</measure>
    <time_frame>5 days</time_frame>
    <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CLr After Multiple Dose Administration (Day 5)</measure>
    <time_frame>5 days</time_frame>
    <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hr Sodium Urinary Excretion in Subjects With Severe Renal Impairment and Their Matched Healthy Volunteers</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Renal Impaired</condition>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Renal Impaired Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily administration of 400 mg LCZ696 for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily administration of 400 mg LCZ696 for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696A</intervention_name>
    <arm_group_label>Renal Impaired Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696A</intervention_name>
    <description>once daily administration of 400 mg LCZ696 for 5 days</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <results_first_submitted>July 30, 2015</results_first_submitted>
  <results_first_submitted_qc>August 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2015</results_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LCZ696</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Severe Renal Impaired Subjects</title>
          <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Matched Healthy Volunteers</title>
          <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min.Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Severe Renal Impaired Subjects</title>
          <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement.
Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Matched Healthy Volunteers</title>
          <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min.
Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="7.76"/>
                    <measurement group_id="B2" value="52.5" spread="6.98"/>
                    <measurement group_id="B3" value="53.2" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <time_frame>1 and 5 days</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <population>Pharmacokinetic analysis set</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 (Sacubitril) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.5" upper_limit="1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377 (Sacubitril) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657(Sacubitril pro-drug) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657(Sacubitril pro-drug) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 hr Sodium Urinary Excretion in Subjects With Severe Renal Impairment and Their Matched Healthy Volunteers</title>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>24 hr Sodium Urinary Excretion in Subjects With Severe Renal Impairment and Their Matched Healthy Volunteers</title>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.658" spread="79.9239"/>
                    <measurement group_id="O2" value="177.833" spread="39.5533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.000" spread="35.5564"/>
                    <measurement group_id="O2" value="187.000" spread="42.8392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.333" spread="34.5714"/>
                    <measurement group_id="O2" value="156.833" spread="26.4607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.050" spread="39.6424"/>
                    <measurement group_id="O2" value="145.500" spread="31.5325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.683" spread="21.3792"/>
                    <measurement group_id="O2" value="140.500" spread="30.9629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.500" spread="36.2171"/>
                    <measurement group_id="O2" value="156.667" spread="32.1165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.400" spread="23.1383"/>
                    <measurement group_id="O2" value="96.167" spread="28.6316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.150" spread="36.1899"/>
                    <measurement group_id="O2" value="107.667" spread="57.4514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Cmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <time_frame>1 and 5 days</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>(Cmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <population>Pharmacokinetic analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 (Sacubitril)on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5215" spread="3220"/>
                    <measurement group_id="O2" value="2810" spread="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377(Sacubitril) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4960" spread="3430"/>
                    <measurement group_id="O2" value="2407" spread="1780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 (Sacubitril prodrug)on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15967" spread="3380"/>
                    <measurement group_id="O2" value="14633" spread="2233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 ( Sacubitril prodrug) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30650" spread="11462"/>
                    <measurement group_id="O2" value="18233" spread="1975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5935" spread="2191"/>
                    <measurement group_id="O2" value="4988" spread="1093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5852" spread="3306"/>
                    <measurement group_id="O2" value="5672" spread="1314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-24h After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
        <time_frame>1 and 5 days</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-24h After Single Dose (Day 1), and After Multiple Dose Administration (Day 5)</title>
          <population>Pharmacokinetic analysis set</population>
          <units>(hr*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 (Sacubitril) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5918" spread="3430.4"/>
                    <measurement group_id="O2" value="4101" spread="815.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AHU377(Sacubitril) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5495" spread="2890.2"/>
                    <measurement group_id="O2" value="4336" spread="745.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657(Sacubitril prodrug) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254000" spread="72562"/>
                    <measurement group_id="O2" value="146100" spread="17346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 (Sacubitril prodrug) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="538300" spread="268650"/>
                    <measurement group_id="O2" value="185500" spread="29759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40560" spread="11344"/>
                    <measurement group_id="O2" value="29870" spread="8756.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51080" spread="33780"/>
                    <measurement group_id="O2" value="32470" spread="8687.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 After Multiple Dose Administration (Day 5)</title>
        <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 After Multiple Dose Administration (Day 5)</title>
          <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
          <population>Pharmacokinetic analysis set</population>
          <units>(hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 (Sacubitril)on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.030" spread="1.2793"/>
                    <measurement group_id="O2" value="1.916" spread="0.69234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657(Sacubitril prodrug) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.55" spread="17.301"/>
                    <measurement group_id="O2" value="13.16" spread="2.6829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.40" spread="9.1992"/>
                    <measurement group_id="O2" value="12.98" spread="2.9882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F After Multiple Dose Administration (Day 5)</title>
        <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F After Multiple Dose Administration (Day 5)</title>
          <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
          <population>Pharmacokinetic analysis set</population>
          <units>(ml/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377(Sacubitril) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45100" spread="24523"/>
                    <measurement group_id="O2" value="45900" spread="8168.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657( Sacubitril prodrug) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">LBQ657 is a metabolite of AHU377, and hence LBQ657 CL/F values are not relevant.</measurement>
                    <measurement group_id="O2" value="NA">LBQ657 is a metabolite of AHU377, and hence LBQ657 CL/F values are not relevant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7370" spread="8063.0"/>
                    <measurement group_id="O2" value="6792" spread="2051.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CLr After Multiple Dose Administration (Day 5)</title>
        <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Impaired Subjects</title>
            <description>Subjects with severe (CrCl from &lt;30 mL/min), renal function who were otherwise in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.8°C, systolic blood pressure (95-180 mm Hg), diastolic blood pressure (60-110 mm Hg), pulse rate (54-95 bpm), laboratory tests and urinalysis. Creatinine clearance (CrCl) was calculated by the Cockcroft-Gault (CG) formula with patient stratification based on the screening serum creatinine measurement.Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>All healthy volunteers were matched by age (±5 years), sex and BMI (±10%) to the renal subjects enrolled into the study. Subjects were to be in good health as determined by past medical history, physical examination, electrocardiogram, vital signs (measured after 3 minutes rest in the supine position) which are within the following ranges; oral body temperature between 35.0-37.2 °C, systolic blood pressure (95-140 mm Hg), diastolic blood, pressure (60-100 mm Hg), pulse rate (45-90 bpm), laboratory tests and urinalysis. Healthy subjects must have a CrCl of &gt;80 mL/min. Once daily administration of 400 mg LCZ696 p.o. for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>CLr After Multiple Dose Administration (Day 5)</title>
          <description>Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696</description>
          <population>Pharmacokinetic analysis set</population>
          <units>(ml/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AHU377 (Sacubitril) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.18" spread="28.781"/>
                    <measurement group_id="O2" value="111.8" spread="82.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LBQ657 (Sacubitril prodrug) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.39" spread="38.392"/>
                    <measurement group_id="O2" value="436.9" spread="72.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAL489 (valsartan) on day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.89" spread="20.781"/>
                    <measurement group_id="O2" value="299.4" spread="97.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events are monitored from date of First Subject First Visit (FSFV) until Last Subject Last Visit (LSLV). All other adverse events are monitored from First Subject First Treatment (FSFT) until Last Subject Last Visit (LSLV).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Severe Renal Impaired Patients</title>
        </group>
        <group group_id="E2">
          <title>Matched Healthy Volunteers</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postural orthostatic tachycardia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Orthostatic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

